...
首页> 外文期刊>Diabetes & vascular disease research: official journal of the International Society of Diabetes and Vascular Disease >Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.
【24h】

Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.

机译:在接受急性缺血性卒中的2型糖尿病患者中,事先用二肽基肽酶4抑制剂治疗与更好的功能结局和更低的院内死亡率相关。

获取原文
获取原文并翻译 | 示例
           

摘要

It is unclear whether prior antidiabetic treatment affects stroke severity and outcome. To evaluate this association, we prospectively studied all patients who were admitted in our Department with acute ischaemic stroke (n?=?378, mean age?=?78.8?±?6.5?years). The severity of stroke was assessed at admission with the National Institutes of Health Stroke Scale. The outcome was assessed with the modified Rankin Scale at discharge and with in-hospital mortality. A total of 123 patients had type 2 diabetes mellitus. At admission, there was a trend for lower National Institutes of Health Stroke Scale in patients treated with dipeptidyl peptidase 4 inhibitors compared with patients treated with other antidiabetic agents (6.1?±?7.5 vs 10.0?±?9.2, respectively; p?=?0.079). At discharge, patients treated with dipeptidyl peptidase 4 inhibitors had lower modified Rankin Scale than patients treated with other antidiabetic agents (2.1?±?1.9 vs 3.2?±?2.1, respectively; p?
机译:目前尚不清楚以前的抗糖尿病治疗是否会影响中风的严重程度和预后。为了评估这种关联,我们前瞻性地研究了在本科住院的所有急性缺血性卒中患者(n = 378,平均年龄= 78.8±6.5岁)。入院时使用国立卫生研究院卒中量表评估卒中的严重程度。通过改良出院时的兰金量表和住院死亡率评估结局。共有123位患者患有2型糖尿病。入院时,与其他抗糖尿病药相比,接受二肽基肽酶4抑制剂治疗的美国国立卫生研究院卒中量表有降低的趋势(分别为6.1?±?7.5和10.0?±?9.2; p?=?)。 0.079)。出院时,接受二肽基肽酶4抑制剂治疗的患者的改良Rankin Scale低于接受其他抗糖尿病药治疗的患者(分别为2.1%±1.9%vs 3.2%±2.1%; p <0.05)。用二肽基肽酶4抑制剂治疗的患者的院内死亡率也比用其他抗糖尿病药治疗的患者低(分别为0.0%和15.1%; p <0.05)。总之,在急性缺血性卒中患者中预先用二肽基肽酶4抑制剂治疗似乎与改善功能预后和降低死亡风险有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号